만성 C형 간염에서 페그인터페론과 리바비린의 병합치료시 치료 순응도의 중요성

• Published in: The Korean journal of gastroenterology Vol. 57; no. 5; pp. 294 - 301
• Main Authors: 이헌영, Heon Young Lee, 고평곤, Pyung Gohn Goh, 김민정, Min Jung Kim, 김혜진, Hye Jin Kim, 은혁수, Hyuk Soo Eun, 김의식, Eui Sik Kim, 김윤정, Yun Jeung Kim, 이수윤, Soo Youn Lee, 문희석, Hee Seok Moon, 이엄석, Eaum Seok Lee, 김석현, Seok Hyun Kim, 이병석, Byung Seok Lee
• Format: Journal Article
• Language: Korean
• Published: 대한소화기학회 30.05.2011
• Subjects: Hepatitis C; Medication adherence; Peginterferon; Ribavirin; 내과학
• ISSN: 1598-9992; 2233-6869

Background/Aims: The combination therapy with peginterferon and ribavirin is a standard treatment for patients with chronic hepatitis C. However, because of the long duration of the treatment and many complications, the reduction of adherence frequently occur. This study aimed to assess influences of reduced medication adherence in the combination therapy of chronic hepatitis C patients. Methods: We retrospectively reviewed the medical records of 82 patients with chronic hepatitis C who received a combination therapy with peginterferon and ribavirin. The patients were categorized into 3 subgroups on the basis of medication adherence. Group 1 comprised patients who received ≥80% of the recommended dosage of both peginterferon and ribavirin. Group 2 comprised those patients who received ≥80% of the recommended dosage of only 1 drug. The patients of Group 3 received <80% of the recommended dosage of both the drugs. Results: Sustained virologic response (SVR)s of patients in Group 1, 2 and 3 were 85.4% (41/48), 85.7% (18/21), and 38.5% (5/13), respectively (p=0.002). SVRs of genotype 1 patients in Group 1, 2 and 3 were 84.2% (16/19), 75% (9/12), and 14.3% (1/7), respectively (p=0.003). SVRs of genotype non-1 patients in Group 1, 2 and 3 were 86.2% (25/29), 100% (9/9), and 66.7% (4/6), respectively (p=0.196). Furthermore are SVRs significantly differed with the degree of medication adherence to either peginterferon or ribavirin (p=0.003 and 0.021, respectively). In multivariate analysis, the peginterferon dose was a significant independent factor associated with SVR. Conclusions: Medication adherence of chronic hepatitis C patients to the combination therapy with peginterferon and ribavirin is very important for achieving SVR. In particular, we think that genotype 1 patients should maintain higher adherence than genotype non-1 patients. (Korean J Gastroenterol 2011;57:294-301)